226 related articles for article (PubMed ID: 22006152)
1. Penile paraffinoma developing during treatment with pegylated interferon alfa-2a for chronic hepatitis C virus infection.
Bachmeyer C; Moguelet P; Gombeaud T; Sbidian E; Aractingi S
Arch Dermatol; 2011 Oct; 147(10):1232-3. PubMed ID: 22006152
[No Abstract] [Full Text] [Related]
2. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
Hu CC; Chien RN
Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
[No Abstract] [Full Text] [Related]
3. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
Castellanos González M; Pérez Carreras M; Muñoz Gómez R; Castellano Tortajada G
Gastroenterol Hepatol; 2011 Oct; 34(8):584-5. PubMed ID: 21641684
[No Abstract] [Full Text] [Related]
4. Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
Papastergiou V; Skorda L; Lisgos P; Karatapanis S
Acta Gastroenterol Belg; 2011 Dec; 74(4):582-4. PubMed ID: 22319972
[No Abstract] [Full Text] [Related]
5. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
Rogers CJ; Romagosa R; Vincek V
J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
[No Abstract] [Full Text] [Related]
6. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.
Chou R; Carson S; Chan BK
J Viral Hepat; 2008 Aug; 15(8):551-70. PubMed ID: 18482285
[TBL] [Abstract][Full Text] [Related]
7. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
8. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
9. Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
Testino G; Gentile R; Ansaldi F; Borro P; Ravetti G; Icardi G; Sumberaz A
Panminerva Med; 2009 Jun; 51(2):135-6. PubMed ID: 19776716
[No Abstract] [Full Text] [Related]
10. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
11. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity.
Yasui S; Fujiwara K; Yokosuka O
Dig Liver Dis; 2011 Aug; 43(8):666-7. PubMed ID: 21435960
[No Abstract] [Full Text] [Related]
13. Repeated Panniculitis Induced by Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis C.
Song JS; Sohn JH; Jeong JY; Min JH; Choi WS; Kim OZ; Pyo JY
Korean J Gastroenterol; 2016 May; 67(5):272-276. PubMed ID: 27206440
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
[TBL] [Abstract][Full Text] [Related]
15. Erythema gyratum repens induced by pegylated interferon alfa for chronic hepatitis C.
Rongioletti F; Fausti V; Parodi A
Arch Dermatol; 2012 Oct; 148(10):1213-4. PubMed ID: 23069974
[No Abstract] [Full Text] [Related]
16. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection.
Tsilika K; Tran A; Trucchi R; Pop S; Anty R; Cardot-Leccia N; Lacour JP; Ortonne JP; Passeron T
JAMA Dermatol; 2013 Jun; 149(6):675-7. PubMed ID: 23553009
[TBL] [Abstract][Full Text] [Related]
17. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
[No Abstract] [Full Text] [Related]
18. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
[TBL] [Abstract][Full Text] [Related]
19. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
Quinn D; Kuchler E; Deming P; Arora S
Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
[No Abstract] [Full Text] [Related]
20. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
